Skip to main content

Table 1 Patients’ characteristics

From: Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood

  

N = 29

 

Age (years)

Mean

64

 

Median (range)

65

(39–81)

Gender n (%)

Male

19

(65.5)

Female

10

(34.5)

Performance status n (%)

0

13

(44.8)

1

16

(55.2)

Histologic subtype n (%)

Adenocarcinoma

9

(31.0)

Squamous cell

17

(58.6)

Neuro-endocrine

3

(10.4)

Stage n (%)

II

4

(13.8)

III

21

(72.4)

IV

4

(13.8)

Chemotherapy n (%)

Platinum doublet

26

(89.6)

Monotherapy

3

(10.4)

Radiation dose (gray)

Mean

61.6

 

Median (range)

66

(37–70)